TASK Act

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: H.R. 1492, Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025. To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Section 340B Public Health Services Act 340B engagement and MFN related engagement Provisions related to the 340B program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Biopharmaceutical innovation and pricing issues HR 5509, Safe Step Act, Provisions related step therapy protocols Tariff and MFN issues VICP Bill

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 2710: Open Payments Expansion Act S. 3345: PBM Price Transparency and Accountability Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Acccess to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 2821: FDA Modernization Act 3.0 H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1836 - Ocean Shipping Reform Implementation Act of 2023 H.R. 3039 - the Deregulating Restrictions on Interstate Vehicles and Eighteen-Wheelers (DRIVE) Act H.R. 3408 - The DRIVE Safe Integrity Act H.R. 2367 - Truck Parking Safety Improvement Act H.R. 3013 / S. 1649 - the LICENSE Act H.R. 2948 - The Carrying Automobiles Responsibly and Safely (CARS) Act H.R. 3318 - the Dry Bulk Weight Tolerance Act H.R. 3447 - to provide a weight exemption for hydrogen vehicles H.R. 3869 - the Trucker Bathroom Access Act H.R. 1440 and S. 694 - Modern, Clean, and Safe Trucks Act of 2023 H.R. 267 - Ceasing Age-Based Trucking Restrictions Act Implementation of Public Law 1178 - Infrastructure Investment and Jobs Act (H.R. 2037/S. 864) Implementation of H.R 4996 / S. 3580 - Ocean Shipping Reform Act Other Trucking issues include Hazardous Materials, Government Traffic, Hours of Service, Public Private Partnerships, Tolling, Background Check, Highway Funding, Transportation Worker ID, Fuel Supply and Cost Issues, Economic Issues and Federal Pre-emption.

Client expense: $680,000 · Firm income: Not reported

Implementation of Public Law 1178 - Infrastructure Investment and Jobs Act (H.R. 2037/S. 864) Implementation of H.R 4996 / S. 3580 - Ocean Shipping Reform Act H.R.2367 / S.1034 - Truck Parking Safety Improvement Act H.R. 267 - Ceasing Age-Based (CAB) Trucking Restrictions Act H.R.471 - Safer Highways and Increased Performance for Interstate Trucking (SHIP IT) Act H.R.2450 - Strengthening Supply Chains Through Truck Driver Incentives Act of 2023 H.R. 1 - Lower Energy Costs Act Other Trucking issues include Hazardous Materials, Government Traffic, Hours of Service, Public Private Partnerships, Tolling, Background Check, Highway Funding, Transportation Worker ID, Fuel Supply and Cost Issues, Economic Issues and Federal Pre-emption.

Client expense: $690,000 · Firm income: Not reported